EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IGF2BP3 mediates the mRNA degradation of NF1 to promote triple‐negative breast cancer progression via an m6A‐dependent manner

Xu Zhang, Liang Shi, Han-Dong Sun, Zi-Wen Wang, Feng Xu, Ji-Fu Wei, Qiang Ding iD

Clinical and Translational Medicine · 2023-09 · 13 (9)

DOI: 10.1002/ctm2.1427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 24.09.2023. Verfasst von Xu Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Breast Disease Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Neurofibromin 1, RNA Stability, Triple Negative Breast Neoplasms, RNA-Binding Proteins. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

N6‐methyladenosine (m6A) is an abundant reversible modification in eukaryotic mRNAs. Emerging evidences indicate that m6A modification plays a vital role in tumourigenesis. As a crucial reader of m6A, IGF2BP3 usually mediates the stabilisation of mRNAs via an m6A‐dependent manner. But the underlying mechanism of IGF2BP3 in the tumourigenesis of triple‐negative breast cancer (TNBC) is unclear.

Methods

TCGA cohorts were analysed for IGF2BP3 expression and IGF2BP3 promoter methylation levels in different breast cancer subtypes. Colony formation, flow cytometry assays and subcutaneous xenograft were performed to identify the phenotype of IGF2BP3 in TNBC. RNA/RNA immunoprecipitation (RIP)/methylated RNA immunoprecipitation (MeRIP) sequencing and luciferase assays were used to certify the target of IGF2BP3 in TNBC cells.

Results

IGF2BP3 was highly expressed in TNBC cell lines and tissues. TET3‐mediated IGF2BP3 promoter hypomethylation led to the upregulation of IGF2BP3. Knocking down IGF2BP3 markedly reduced the proliferation of TNBC in vitro and in vivo. Intersection co‐assays revealed that IGF2BP3 decreased neurofibromin 1 (NF1) stabilisation via an m6A‐dependent manner. NF1 knockdown could rescue the phenotypes of IGF2BP3 knockdown cells partially.

Conclusion

TET3‐mediated IGF2BP3 accelerated the proliferation of TNBC by destabilising NF1 mRNA via an m6A‐dependent manner. This suggests that IGF2BP3 could be a potential therapeutic target for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromin 1RNA StabilityTriple Negative Breast NeoplasmsRNA-Binding ProteinsHumansCarcinogenesisCell Transformation, NeoplasticRNA

Stichwörter der Autor:innen

IGF2BP3NF1TET3TNBCm6A

Substanzen

Neurofibromin 1RNANF1 protein, humanIGF2BP3 protein, humanRNA-Binding Proteins

Autor:innen und Institutionen

  • Jiangsu Breast Disease Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Department of Pharmacy, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing, China.

ORCID-Profile: Qiang Ding

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., Shi, L., Sun, H. D., Wang, Z. W., Xu, F., Wei, J. F., & Ding, Q. (2023). IGF2BP3 mediates the mRNA degradation of NF1 to promote triple‐negative breast cancer progression via an m6A‐dependent manner. Clinical and Translational Medicine, 13(9). https://doi.org/10.1002/ctm2.1427

Vancouver

Zhang X, Shi L, Sun HD, Wang ZW, Xu F, Wei JF, et al. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple‐negative breast cancer progression via an m6A‐dependent manner. Clinical and Translational Medicine. 2023;13(9). doi:10.1002/ctm2.1427

BibTeX
@article{Zhang2023,
  author = {Zhang, Xu and Shi, Liang and Sun, Han-Dong and Wang, Zi-Wen and Xu, Feng and Wei, Ji-Fu and Ding, Qiang},
  title = {IGF2BP3 mediates the mRNA degradation of NF1 to promote triple‐negative breast cancer progression via an m6A‐dependent manner},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  volume = {13},
  number = {9},
  doi = {10.1002/ctm2.1427}
}
Kostenlos starten →